MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Fulgent Genetics Operating Expenses 2011-2026 | FLGT
Annual Operating Expenses Fulgent Genetics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 181 M | 300 M | 188 M | 101 M | 41.7 M | 18.8 M | 15.7 M | 13.7 M | 10.6 M | 9.52 M | 1.33 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 300 M | 1.33 M | 80.2 M |
Quarterly Operating Expenses Fulgent Genetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.9 M | 54.1 M | 48.1 M | - | 43.8 M | 45.4 M | 43.9 M | - | 39.6 M | 40.4 M | 43.6 M | - | 45.7 M | 52.5 M | 40.6 M | 38.7 M | 25.1 M | 18.9 M | 18.4 M | 17.3 M | 11.9 M | 6.91 M | 5.61 M | 5.16 M | 4.95 M | 4.51 M | 4.22 M | 3.93 M | 3.86 M | 3.86 M | 4.08 M | 3.81 M | 3.72 M | 2.91 M | 3.23 M | 2.73 M | 3.56 M | 1.59 M | 2.75 M | 7.52 M | 807 K | 663 K | 530 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 54.1 M | 530 K | 19 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Biodesix
BDSX
|
106 M | $ 15.15 | -2.51 % | $ 1.96 B |  USA |
 |
Biomerica
BMRA
|
5.64 M | $ 2.16 | - | $ 4.96 M | USA |
 |
BioNano Genomics
BNGO
|
41.3 M | $ 1.2 | 1.69 % | $ 6.53 M | USA |
 |
Bioventus
BVS
|
217 M | $ 9.16 | 0.11 % | $ 610 M | USA |
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M |  Israel |
 |
DarioHealth Corp.
DRIO
|
49.3 M | $ 7.7 | -0.77 % | $ 30.7 M | Israel |
 |
DexCom
DXCM
|
1.89 B | $ 66.84 | 0.36 % | $ 26.1 B | USA |
 |
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
2.47 B | $ 104.91 | - | $ 19.8 B | USA |
 |
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
37.1 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
45.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | China |
 |
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
607 M | $ 165.89 | 4.21 % | $ 8.22 B | USA |
 |
ICON Public Limited Company
ICLR
|
408 M | $ 99.99 | -1.27 % | $ 8.25 B |  Irlanda |
 |
Illumina
ILMN
|
3.69 B | $ 126.2 | 0.17 % | $ 20.1 B | USA |
 |
IQVIA Holdings
IQV
|
2.94 B | $ 165.64 | -0.27 % | $ 28.5 B | USA |
 |
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | USA |
 |
ENDRA Life Sciences
NDRA
|
10.8 M | $ 3.75 | 8.38 % | $ 2.01 M | USA |
 |
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | USA |
 |
Lantheus Holdings
LNTH
|
123 M | $ 75.63 | 1.87 % | $ 5.1 B | USA |
 |
Interpace Biosciences
IDXG
|
21.8 M | $ 1.69 | -1.31 % | $ 7.41 M | USA |
 |
Medpace Holdings
MEDP
|
118 M | $ 466.8 | 1.32 % | $ 13.5 B | USA |
 |
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B |  Niderland |
 |
Myriad Genetics
MYGN
|
964 M | $ 4.68 | 1.52 % | $ 433 M | USA |
 |
National Research Corporation
NRC
|
38.5 M | $ 17.18 | -1.49 % | $ 385 M | USA |
 |
Natera
NTRA
|
258 M | $ 197.37 | 1.47 % | $ 19.4 B | USA |
 |
Celcuity
CELC
|
113 M | $ 110.22 | 8.05 % | $ 4.35 B | USA |
 |
Organovo Holdings
ONVO
|
23.3 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
21.9 M | - | -16.95 % | $ 1.54 M | USA |
 |
OPKO Health
OPK
|
217 M | $ 1.19 | 5.31 % | $ 826 M | USA |
 |
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 266.02 | -0.04 % | $ 22.1 B | USA |
 |
Pacific Biosciences of California
PACB
|
600 M | $ 1.39 | - | $ 417 M | USA |
 |
NeoGenomics
NEO
|
430 M | $ 7.77 | -1.15 % | $ 995 M | USA |
 |
Psychemedics Corporation
PMD
|
11.3 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
13.6 M | $ 27.24 | 2.41 % | $ 35.4 M | USA |
 |
Personalis
PSNL
|
44.5 M | $ 7.7 | -1.03 % | $ 456 M | USA |